Transgene SA has reported positive results of an exploratory Phase Ib/II study in HPV-16-positive cancers combining its cancer vaccine TG4001 with Merck KgaA’s PD-L1 blocker avelumab.
Roche AG has paid US$350 in cash to co.develop and market Atea Pharmaceutical’s oral direct-acting antiviral, AT-527, to limit proliferation of SARS-CoV-2.
New ADC company Araris Biotech has got backing by Pureos Bioventures and co-investors in a CHF15.2m seed round to develop a new class of antibody drug conjugates.
·
Vifor Pharma and Cara Therapeutics have signed a US license agreement for Korsuva to treat dialysis patients with pruritus.
Atriva Therapeutics has secured a €24m loan to push the development of its COVID-19 programme ATR-002, an antiviral, anti-inflammatory MEK inhibitor.
Topas Therapeutics GmbH will use the €22m proceeds from a Series B Financing to advance two pipeline candidates.
Siemens Healthineers has launched its Clinitest Rapid COVID-19 Antigen Test in Europe, which can identify persons infected with SARS-CoV-2 in 15 minutes.
Priothera Ltd. wants to use €30m from a Series A financing to develop a licenced therapy for acute myeloid leukemia (AML).
Johnson & Johnson (JNJ) has inked a contract with the European Commission to supply 200 million doses of its COVID-19 vaccine to the European Union.
Swiss Santhera Pharmaceuticals has discontinued Phase III development of its DMD drug and will restructure its pipeline.